

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark  
Office  
(Box PCT)  
Crystal Plaza 2  
Washington, DC 20231  
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year)

26 February 1999 (26.02.99)

International application No.

PCT/JP98/02613

Applicant's or agent's file reference

PWO-17050

International filing date (day/month/year)

15 June 1998 (15.06.98)

Priority date (day/month/year)

17 June 1997 (17.06.97)

Applicant

MIYAKE, Hiroshi et al

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

02 December 1998 (02.12.98)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

K. Takeda

Telephone No.: (41-22) 338.83.38

## PATENT COOPERATION TREATY

PCT

NOTIFICATION CONCERNING  
SUBMISSION OR TRANSMITTAL  
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU

To:

SEKI, Hideo  
Fujisawa Pharmaceutical Co., Ltd.  
Osaka Factory  
1-6, Kashima 2-chome  
Yodogawa-ku, Osaka-shi  
Osaka 532-8514  
JAPON

Date of mailing (day/month/year) 27 July 1998 (27.07.98)	
Applicant's or agent's file reference PWO-17050	<b>IMPORTANT NOTIFICATION</b>
International application No. PCT/JP98/02613	International filing date (day/month/year) 15 June 1998 (15.06.98)
International publication date (day/month/year) Not yet published	Priority date (day/month/year) 17 June 1997 (17.06.97)
Applicant FUJISAWA PHARMACEUTICAL CO., LTD. et al	

1. The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise indicated by an asterisk appearing next to a date of receipt, or by the letters "NR", in the right-hand column, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
2. This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.
3. An asterisk(\*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
4. The letters "NR" appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
17 June 1997 (17.06.97)	PO7359	AU	17 July 1998 (17.07.98)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Sean Taylor <i>Seal Taylor</i>
Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38

# PATENT COOPERATION TREATY

PCT/JP98/02613

**PCT**

## NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

From the INTERNATIONAL BUREAU

To:

SEKI, Hideo  
Fujisawa Pharmaceutical Co., Ltd.  
Osaka Factory  
1-6, Kashima 2-chome  
Yodogawa-ku, Osaka-shi  
Osaka 532-8514  
JAPON

Date of mailing (day/month/year)

23 December 1998 (23.12.98)

Applicant's or agent's file reference

PWO-17050

### IMPORTANT NOTICE

International application No.

PCT/JP98/02613

International filing date (day/month/year)

15 June 1998 (15.06.98)

Priority date (day/month/year)

17 June 1997 (17.06.97)

Applicant

FUJISAWA PHARMACEUTICAL CO., LTD. et al

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:

AU,BR,CA,CN,EP,IL,JP,KR,PL,US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:

AL,AM,AP,AT,AZ,BA,BB,BG,BY,CH,CU,CZ,DE,DK,EA,EE,ES,FI,GB,GE,HU,IS,KE,KG,KZ,LC,LK,  
LR,LS,LT,LU,LV,MD,MG,MK,MN,MW,MX,NO,NZ,OA,PT,RO,RU,SD,SE,SG,SI,SK,TJ,TM,TR,TT,UA,  
UG,UZ,VN

The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on 23 December 1998 (23.12.98) under No. WO 98/57954

### REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

### REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Authorized officer

J. Zahra

Facsimile No. (41-22) 740.14.35

Telephone No. (41-22) 338.83.38

**NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF  
THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES**

<b>Date of mailing (day/month/year)</b> 23 December 1998 (23.12.98)	<b>IMPORTANT NOTICE</b>
<b>Applicant's or agent's file reference</b> PWO-17050	<b>International application No.</b> PCT/JP98/02613
<p>The applicant is hereby notified that, at the time of establishment of this Notice, the time limit under Rule 46.1 for making amendments under Article 19 has not yet expired and the International Bureau had received neither such amendments nor a declaration that the applicant does not wish to make amendments.</p>	

# PATENT COOPERATION TREATY

## PCT

REC'D 07 SEP 1999

WIPO PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>PWO-17050</b>	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. <b>PCT/JP98/02613</b>	International filing date (day/month/year) <b>15/06/1998</b>	Priority date (day/month/year) <b>17/06/1997</b>
International Patent Classification (IPC) or national classification and IPC <b>C07D401/06</b>		
Applicant <b>FUJISAWA PHARMACEUTICAL CO., LTD. et al.</b>		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 8 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand <b>02/12/1998</b>	Date of completion of this report <b>03. 09. 99</b>
Name and mailing address of the international preliminary examining authority:  <b>European Patent Office D-80298 Munich Tel. (+49-89) 2399-0 Tx: 523656 epmu d Fax: (+49-89) 2399-4465</b>	Authorized officer <b>Hartrampf, G</b> Telephone No. (+49-89) 2399 

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/JP98/02613

## I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

### Description, pages:

1-180 as originally filed

### Claims, No.:

1-10 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

## III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 8.

because:

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/JP98/02613

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 8.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes:	Claims 4
	No:	Claims 1-3,5-10
Inventive step (IS)	Yes:	Claims
	No:	Claims 1-10
Industrial applicability (IA)	Yes:	Claims 1-7,9,10
	No:	Claims

**2. Citations and explanations**

**see separate sheet**

**VI. Certain documents cited**

**1. Certain published documents (Rule 70.10)**

and / or

**2. Non-written disclosures (Rule 70.9)**

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/JP98/02613

---

**VII. Certain defects in the international application**

The following defects in the form or contents of the international application have been noted:

**see separate sheet**



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/JP98/02613

**ad section III**

For the assessment of the present claim 8 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**ad section V**

**1. PRIOR ART**

The following documents cited in the International search report were taken into consideration

EP 0 655 442 A

(D1)

WO 96 34864 A

(D2)

WO 96 37489 A

(D3)

WO 97 08166 A

(D4).

PRIOR  
5/31/1995

**2. NOVELTY**

With regard to the prior art documents cited above the subject-matter claimed, i.e. aroyl-piperazine derivatives according to the formula in claim 1, does **not** appear to fulfil the requirements of novelty, cf. Article 33(2) PCT.

There exist several overlaps of the present compounds with those disclosed in documents D1 to D4.

INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET

International application No. PCT/JP98/02613

*412 Malv*

- (3) (i) The compounds of formula (I) in D1 wherein (D1 nomenclature) X is CO, R<sup>2</sup> is (un)substituted aryl or (un)substituted aromatic heterobicyclic group, R<sup>4</sup> is -A-(Z)<sub>p</sub>, A is a bond, alkylene, alkenylene or alkynylene, Z is (un)substituted aromatic hetero(mono- or bi-)cyclic group and in particular those of table 1, see esp. examples 50-44 and 50-48 are covered by present claims 1-3, 5-7, 9 and 10.
- (2) (ii) The compounds of formula (I) in D2 wherein (D2 nomenclature) Ar<sub>1</sub> is (un)substituted phenyl or naphthyl, X is O, l is zero, n is 1, Ar<sub>2</sub> is (un)substituted heteroaryl, phenyl or naphthyl, R<sub>c</sub> is hydrogen or alkyl, X is (H,H) and Z is one of these heterocyclicimino groups are covered by present claims 1, 2, 6, 7, 9 and 10. *464 31we*
- (1) (iii) The compounds of claims 1 and 8 in D3 are covered by present claims 1, 5-7, 9 and 10. *489 Malv*
- (4) (iv) The compounds of formula (I) in D4 wherein (D4 nomenclature) Ar<sub>1</sub> is (un)substituted phenyl or naphthyl, X is O, l is zero, n is 1, Ar<sub>2</sub> is (un)substituted heteroaryl, phenyl or naphthyl, R<sub>c</sub> is hydrogen or alkyl, X is (H,H) and Z is substituted piperidinylimino are covered by present claims 1, 6, 7, 9 and 10. *166*

Thus at present claims 1-3 and 5-10 cannot be considered to be novel. The Applicant is invited to remove any overlap existing between the present application and the disclosures of the prior art. As a precautionary measure it is pointed out to the Applicant that the disclosure in a prior document likely to affect the novelty of a claim is not necessarily limited to the specific working examples but also comprises any reproducible technical teaching described in the document.

### 3. INVENTIVE STEP

- 3.1. The present application is directed to aroyl-piperazine derivatives which are neurokinin antagonists.

From the prior art available so far the following is known. Documents D1 to D4 disclose already aroyl-piperazine derivatives which are (at least partially) identical to the present compounds. These compounds are additionally neurokinin

antagonists thus exhibiting the same properties as the compounds presently claimed.

- 3.2. In order to establish an inventive step in the sense of Article 33(3) PCT, it appears to be necessary to restrict the claims to compound(group)s that represent a reasonable generalisation of the examples given, that is, for which it can be made credible that they indeed possess the alleged properties. It should be borne in mind that a technical effect which justifies the selection of the claimed compounds must be one which can be fairly assumed to be produced by substantially all the selected compounds.

Due to lack of any experimental test data and/or pharmacological data which could be related to single compounds and/or convincing arguments it is for the time being not clearly evident that the problem has actually been solved.

#### **4. INDUSTRIAL APPLICABILITY**

Insofar the presently claimed compounds exhibit said pharmaceutical properties no objection arises, cf. Article 33(4) PCT.

Claim 8 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of this claim, cf. Article 34(4)(a)(i) PCT.

#### **ad section VI**

WO 97 22597 A  
16.05.96

18.12.95  
  
30.09.96

12.12.96

26.06.97

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/JP98/02613

WO 98 08826 A	30.08.96	28.08.97	5.03.98
WO 98 18788 A	30.10.96	28.10.97	7.05.98

The priority documents pertaining to the present application were not available at the time of establishing this international preliminary examination report. Hence, it is based on the assumption that all claims enjoy priority rights from the filing date of the priority document. If it later turns out that this is not correct, the P-documents cited in the international search report could become relevant to assess whether the claims satisfy the criteria set forth in Article 33(1) PCT.

**ad section VII**

1. To meet the requirements of Rule 5.1(a) PCT, all of the documents cited in the International search report should have been identified in the description and the relevant background art disclosed therein should have been briefly discussed.

# INTERNATIONAL SEARCH REPORT

Patent Application No.

PCT/JP 98/02613

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/06 A61K31/495 C07D401/12 C07D401/14 C07D403/06  
C07D403/14 C07D241/04 A61K31/535 A61K31/54 C07D417/14  
C07D413/06 A61K31/55 C07D413/12 C07D407/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 655 442 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 31 May 1995 cited in the application see claims 1-3,6-8; examples 50-44,50-48; table 1 ---	1-3,5-7, 9,10
X	WO 96 34864 A (SCHERING CORPORATION) 7 November 1996 see claims 1,2,4-8.10,22-24 ---	1,2,6,7, 9,10
X	WO 96 37489 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 28 November 1996 see claims 1-7 ---	1,5-7,9, 10
X	WO 97 08166 A (SCHERING CORPORATION) 6 March 1997 see claims 1-3,5,12-14 ---	1,6,7,9, 10
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

21 September 1998

Date of mailing of the international search report

11. 11. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hartrampf, G

# INTERNATIONAL SEARCH REPORT

PCT/JP 93/02613

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 97 22597 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 26 June 1997 cited in the application see examples 45,50-52,56,58-60,63,67,70,77,85,86 see claims 1-7,9-14 ---	1-3,5-7, 9,10
P,X	WO 98 08826 A (SCHERING CORPORATION) 5 March 1998 see claims 1,2,4,12-14 ---	1,2,6,7, 9,10
P,X	WO 98 18788 A (SCHERING CORPORATION) 7 May 1998 see claims 1-4,12-16 -----	1,2,6,7, 9,10

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/JP 98/02613

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Patent Application No.

PCT/JP 93/02613

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0655442 A	31-05-1995	AU 689504 B AU 7911194 A CA 2136712 A CN 1107149 A HU 71348 A JP 7242641 A US 5670505 A ZA 9409228 A BR 9500539 A	02-04-1998 08-06-1995 30-05-1995 23-08-1995 28-11-1995 19-09-1995 23-09-1997 01-08-1995 31-10-1995
WO 9634864 A	07-11-1996	US 5719156 A AU 5714196 A CA 2218887 A CZ 9703423 A EP 0823906 A NO 975028 A PL 323235 A US 5798359 A US 5795894 A AU 6997996 A EP 0850236 A WO 9708166 A NO 980848 A PL 325339 A	17-02-1998 21-11-1996 07-11-1996 18-03-1998 18-02-1998 30-12-1997 16-03-1998 25-08-1998 18-08-1998 19-03-1997 01-07-1998 06-03-1997 30-04-1998 20-07-1998
WO 9637489 A	28-11-1996	AU 5703196 A EP 0846116 A ZA 9604101 A	11-12-1996 10-06-1998 29-07-1996
WO 9708166 A	06-03-1997	US 5795894 A AU 6997996 A EP 0850236 A NO 980848 A PL 325339 A AU 5714196 A EP 0823906 A NO 975028 A CA 2218887 A CZ 9703423 A PL 323235 A	18-08-1998 19-03-1997 01-07-1998 30-04-1998 20-07-1998 21-11-1996 18-02-1998 30-12-1997 07-11-1996 18-03-1998 16-03-1998



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/JP 93/02613

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9708166 A		WO 9634864 A	07-11-1996
WO 9722597 A	26-06-1997	AU 1110697 A	14-07-1997
WO 9808826 A	05-03-1998	AU 4080097 A	19-03-1998
WO 9818788 A	07-05-1998	AU 4991797 A	22-05-1998